The Food and Drug Administration has pushed back the release of its decision on approval of Moderna’s respiratory syncytial virus vaccine by up to three weeks due to “administrative ...
Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US. The company said the FDA would ...
(Bloomberg) -- US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative constraints” at the Food and Drug Administration, as the ...
The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...
The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only ...
The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory syncytial virus due to “administrative constraints ...
The US Food and Drug Administration (FDA) has approved the messenger RNA-based (mRNA) vaccine against respiratory syncytial virus (RSV) for people ages 60 and older. The vaccine, made by Moderna, is ...
Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's respiratory syncytial virus (RSV) vaccine. Just days before its ...
CIDRAP reports on the approval of Moderna's mRNA vaccine, called mRESVIA, which is expected to be available during the 2024-25 respiratory virus season. Other news is on a rise in whooping cough cases ...